To be successful, one must realize that the GLP-1 Receptor is unlike any other drug target.

Small molecule drug development is hard. It requires designing and developing molecules that show an exquisite balance between efficacy, toxicity, and tolerability. STRIGOSUS has made remarkable progress towards this goal in the area of GLP-1R agonism by developing small molecules that show appetite suppression and weight loss while being extremely well tolerated in animal models of obesity and safety.

How has STRIGOSUS achieved this? By focusing on key concepts.

• Fine-tuning GLP-1R modulation. Think of the Goldilocks principle. One must find the precise amount of agonism to effect benefits while reducing detriments. Particular emphasis must be on limiting excessive modulation.

• Maintaining endogenous signaling. Modulators must enhance GLP-1R signaling in a way that is synergistic with the system as a whole.

• Nuance and subtlety are key.

• Preservation of natural signaling rhythms – avoiding overstimulation or complete shutdown.

• Preservation of physiological signaling patterns.

This has allowed the STRIGOSUS team to develop molecules that offer the potential to maximize therapeutic effects while minimizing adverse effects.